Epidemiologists will examine whether medicinal cannabis users are vulnerable to further complications from COVID-19.
Researchers working at the University of Miami are launching a preliminary study examining the impact of the COVID-19 virus on medicinal cannabis patients.
The study will be used to strengthen epidemiologists understanding of the coronavirus outbreak and will employ patient data to examine their physical and mental health.
If COVID-19 has taught us anything, it is that population-based data is vital to make informed decisions. My team and I understand that the plural of anecdote is not data. So, we are combining our skills to do our part to provide that data. Lead Researcher and Epidemiologist, Denise C Vidot
The preliminary study will be led by Epidemiologist Denise C Vidot and will involve a group of doctors and experts from the School of Nursing and Health Studies, Office of Hemispheric and Global Affairs, and Miller School of Medicine's Department of Public Health Sciences.
The researchers will also be investigating whether the usage of inhalable cannabis form factors—such as vapes, bongs or joints—could be fuelling the spread of COVID-19.
The study's launch is particularly timely, as medical cannabis patients are considered to be a vulnerable group that may be impacted by the coronavirus crisis, potentially due to delays in fulfillment of prescriptions.
Additionally, they may exhibit further vulnerabilities to the coronavirus, such as a compromised immune system or other chronic health conditions.
"Our goal is to have cannabis users from every country complete this survey, so the data is more generalisable," Vidot said.
"The global qualifying conditions for medical cannabis, though not uniform, all include individuals with compromised immune systems and other chronic health conditions."
"Therefore, this is a population that we cannot forget about in our joint effort to 'flatten the curve'."
This pot stock could reach new heights in 2020 due to Coronavirus
The COVID-19 pandemic is showing no signs of slowing down, and as global markets enter meltdown many cannabis companies are feeling the effects of capital crunch.
While the market crash will continue for some time, it represents a golden opportunity for investors who are capable of riding out the volatility until share prices rally.
Luckily, one pot stock has developed antimicrobial drug that can already treat two superbugs while limiting their ability to develop antibiotic resistance.
Investors can also start picking up shares at rock bottom prices, as global investor sentiment continues to dampen thanks to COVID-19.
Get the Latest Marijuana News &
Content in your Inbox!
All your support helps The Green Fund keep writing content for all you
marijuana enthusiasts and potential pot stock investors